Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib + olaparib vs chemotherapy in platinum-resistant/refractory gBRCAnm HGSOC
CTR20212750Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of alpelisib in High-Grade Serous Ovarian Cancer (HGSOC), fallopian tube cancer (PFTC), Endometrioid Cystadenocarcinoma, primary peritoneal cancer (PPC), sponsored by Novartis. Started Nov 2021; status: completed.
02
Drugs
alpelisib
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)fallopian tube cancer (PFTC)Endometrioid Cystadenocarcinomaprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20212750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212750.